Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 772 across all filing types
Latest filing 2025-09-19 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a USFDA inspection at the company's API manufacturing facility with zero observations. It is addressed to stock exchanges and includes a summary of the company's profile and contact information for media inquiries. The document does not contain any financial statements, detailed financial performance data, or regulatory filings. It is a corporate announcement related to operational compliance and quality inspection results rather than a financial report or regulatory filing. The document length is 3536 characters, which is relatively short and typical for a press release. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Management Reports.
2025-09-19 English
Shareholders meeting
Regulatory Filings
2025-09-12 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited, providing a clarification regarding an increase in trading volume of the company's stock. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and states that no undisclosed material information exists that could affect the stock price or volume. The document is a regulatory communication clarifying market behavior and compliance, not a financial report, earnings release, or any other specific report type. It is short (2292 characters) and serves as a regulatory filing or announcement to the stock exchange rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS).
2025-09-12 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is titled 'Proceedings of 78th Annual General Meeting of Indoco Remedies Limited' and details the events and discussions held during the AGM on 11th September 2025. It includes information about the meeting's conduct, attendees, resolutions proposed, and voting procedures. It does not contain the full annual report or financial statements but summarizes the AGM proceedings. The document also mentions that voting results will be submitted later, indicating this is a meeting summary rather than a results announcement or report publication. Therefore, this document fits the category of AGM Information (AGM-R).
2025-09-11 English
Agreements
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to the National Stock Exchange of India Limited and Bombay Stock Exchange Limited, dated 30th August 2025. It informs about a Sale and Lease Back transaction involving movable properties of the company. The letter references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content includes details of the agreements, parties involved, financial terms, and confirms no impact on business operations. The document is an announcement of a material event related to capital structure and asset management, specifically a sale and leaseback transaction. It does not contain financial statements, earnings data, or management discussion. It is not a report but a regulatory disclosure of a corporate transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-08-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing them about an upcoming meeting between the company's senior management and analysts/institutional investors. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an announcement of a scheduled investor meeting, not a report or transcript of the meeting itself. The document length is short (1903 characters), and it does not contain financial data, earnings, or detailed presentations. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about an investor meeting and does not fit other more specific categories like Investor Presentation or Call Transcript, which would contain detailed content or transcripts.
2025-08-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.